Activating mutations in signaling molecules, such as JAK2-V617F, have been associated with myeloproliferative neoplasms (MPNs). Mice lacking the inhibitory adaptor protein Lnk display deregulation of TPO/Mpl signaling pathways and exhibit similar myeloproliferative characteristics to those found in MPN patients, suggesting a role for Lnk in the molecular pathogenesis of these diseases. Here, we showed that Lnk levels are up-regulated and correlate with an increase in the JAK2-V617F mutant allele burden in MPN patients. Using megakaryocytic cells, we demonstrated that Lnk expression is regulated by the TPO-signaling pathway, thus indicating an important negative control loop in these cells. Analysis of platelets derived from MPN patients and megakaryocytic cell lines showed that Lnk can interact with JAK2-WT and V617F through its SH2 domain, but also through an unrevealed JAK2-binding site within its amino-terminus region. In addition, the presence of the V617F mutation causes a tighter association with Lnk. Finally, we found that the expression level of the Lnk protein can modulate JAK2-V617F-dependent cell proliferation and that its different domains contribute to the inhibition of multilineage and megakaryocytic progenitor cell growth in vitro.
INTRODUCTION
Philadelphia-negative myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell (HSC) diseases characterized by deregulated proliferation of one or several myeloid lineages. These heterogeneous and phenotypically-related disorders include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). 1 The molecular pathogenesis of MPNs was poorly understood until the identification of the JAK2-V617F mutant allele. This acquired somatic mutation (valine to phenylalanine substitution at position 617, V617F) renders the kinase constitutively active, confers cytokine hypersensitivity, independent growth to hematopoietic cells and reproduces an MPN phenotype in murine bone marrow transplantation assays. [2] [3] [4] [5] [6] The JAK2-V617F mutant protein has been identified in approximately 95% of PV, 60% of ET, and 50% of PMF patients. 2, 7 Recently, gain-of-function point mutations were identified in the cytoplasmic domain of the myeloproliferative leukemia virus oncogene (MPL), the receptor for thrombopoietin (TPO), in 2% to 5% of ET and PMF patients, respectively. These mutations (MPL-W515L) were shown to induce MPN with marked thrombocytosis in a mouse model. 8, 9 These findings therefore show that abnormal activation of signaling molecules plays an important role in the pathogenesis of MPNs. However, how defects in these molecules can lead to myeloproliferation in patients remains unknown.
Lnk [also known as Src homology 2 (SH2) B3] is a member of the adaptor protein family
composed of SH2-B (SH2B1) and APS (SH2B2). These proteins share common protein-protein interaction domains and motifs: a dimerization domain and proline-rich motifs at the amino-terminus, a pleckstrin homology (PH) and SH2 domains, and a conserved tyrosine at the carboxy-terminus. 10 Lnk-deficient mice have demonstrated the importance of this adaptor as a negative regulator of cytokine signaling during hematopoiesis. Analysis of Lnk -/--derived HSC and myeloid progenitors has shown that Lnk controls TPO-induced self-renewal, quiescence and proliferation of these cells. [11] [12] [13] [14] Moreover, Lnk -/-animals displayed not only disrupted B lymphopoiesis, but also abnormal megakaryopoiesis and erythropoiesis, due to the absence of negative regulation of TPO and erythropoietin (EPO) signaling pathways, respectively. [15] [16] [17] Indeed, Lnk, through its SH2 domain, negatively modulates MPL, and EPO receptor (EPOR) signaling by attenuating JAK2 activation.
Recently, Lnk was also shown to bind and regulate MPL-W515L and JAK2-V617F forms when expressed in hematopoietic cell lines. 11, 18, 19 These results suggest that these mutant proteins can still undergo Lnk negative regulation.
Of interest is the resemblance between the phenotype displayed by Lnk -/-mice and the biological and clinical characteristics found in MPN patients: hypersensitivity to cytokines, increased number of in vitro multilineage (CFU-GEMM), erythroid (CFU-E), and megakaryocytic (CFU-MK)
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From progenitor colonies, high platelet counts, splenomegaly together with fibrosis and extramedullary hematopoiesis. 20, 21 In the present study, we aimed to identify molecular defects in Lnk that might explain the myeloproliferative status in MPN patients, notably in those negative for the JAK2-V617F, MPL and Reactive Thrombocytosis (RT, secondary to post-surgery inflammatory syndrome) patients and 21 healthy individuals were studied and their characteristics are summarized in Table 1 . JAK2-V617F mutation detection was performed by single nucleotide polymorphism genotyping assay on purified granulocytes DNA. 23 27 out of 41 ET patients (66%) were found JAK2-WT and MPL-WT by direct sequencing 24 . The study was approved by the Institutional Review Board of the PV-Nord group.
Informed consent was obtained from all patients in accordance with the Declaration of Helsinki.
Platelets were purified using the platelet-rich plasma (PRP) technique (supplemental data) and resuspended in TRIzol reagent (Invitrogen, Cergy Pontoise, France) for subsequent RNA extraction.
Bone marrow or peripheral blood CD34 + cells were Ficoll-purified (Amersham, Biosciences, Uppsala, Sweden) followed by magnetic-activated cell sorting selection according to the manufacturer's protocol (Miltenyi Biotec, Paris, France). CD34 + cell purity was verified by flow cytometry (over 95%) and 10 5 cells were directly resuspended in Trizol.
Cell cultures and reagents
The human megakaryoblastic UT7/Mpl (clone 5. 
RNA preparation and quantitative real-time PCR

Immunoprecipitation and immunoblotting
Purified platelets were TPO-stimulated or not, washed in PBS and either resuspended in SDS sample buffer or lysed for immunoprecipitation. UT7/Mpl cells were starved before stimulation with TPO.
HEL cells were washed in PBS before EPO-stimulation. All cells were lysed in ice-cold 1% Nonidet P-40 (NP-40) lysis buffer 27 for 30 minutes on ice. Insoluble material was removed by centrifugation at 27 000g for 10 minutes at 4°C and soluble proteins were immunoprecipitated for 2 hours at 4°C.
Immunocomplexes were solubilized in SDS sample buffer, analyzed on SDS-PAGE gels, transferred and subjected to immunoblotting. Antibody complexes were detected with either horseradish peroxidase (HRP)-conjugated sheep anti-mouse or anti-rabbit immunoglobulin (Cell Signaling Technology) and revealed by enhanced chemiluminescence (ECL, GE Healthcare).
GST pull-down experiments
The amino-terminus plus PH domain, SH2 domain and R364M constructs were previously described. 27 The Lnk PH domain (residues 143 to 288) construct was generated by PCR, sequenced and cloned in pGEX to create an in-frame fusion protein with glutathione-S-transferase (GST). The constructs were expressed in BL21 bacteria and purified on glutathione-Sepharose beads (GE Healthcare Amersham).
All cell lysates were incubated with 5 µg of GST fusion protein for 2 hours at 4°C. The precipitated proteins were separated by SDS-PAGE and subjected to immunoblotting.
Lin-progenitor cells purification, retroviral transduction and in vitro colony assays.
Lnk point mutations and retroviral supernatant preparation were previously described. 27 Figure S1 ). Furthermore, Lnk mRNA expression in platelets derived from RT patients was also significantly higher (82 [43-112]) than healthy controls, but relatively similar to JAK2-V617F MPN patients (P= .09). Since RT patients often exhibit elevated serum TPO levels, our findings suggest that Lnk overexpression in these patients is due to an activation of the TPO signaling pathway. No correlation was found between Lnk mRNA levels and most of the clinical and biological parameters examined, including history of thrombosis, splenomegaly, WBC, ANC, Hb, platelet counts and EPO level (Table 1) . However, cytoreductive treatment seemed to affect Lnk mRNA levels: MPN patients treated with interferon-α (IFN-α) displayed significantly lower levels of Lnk mRNA (39 ± 36; n=18) than those treated with hydroxyurea (145 ± 235; n=34; P = .04), suggesting that IFN-α can modulate Lnk expression.
Together, these results show that Lnk is up-regulated in MPNs, notably in those bearing the JAK2-V617F mutation, at the mature cell level, as well as in CD34 + progenitors.
Lnk is regulated by TPO-mediated signaling pathways in megakaryocytes.
The elevated Lnk expression in RT and JAK2-V617F MPN patients suggested that JAK2 was forms displayed high TPO-induced phosphorylation. Altogether, these results suggest that the activation/phosphorylation of JAK2-WT and V617F forms is regulated differently by Lnk in MPN patients.
Lnk associates with active JAK2-WT and V617F via its SH2 domain.
Members of the SH2B family have been shown to directly associate with JAK2 via their SH2 domain and the phosphorylated tyrosine residue 813 (pY813) in JAK2. This association is required for the regulation of JAK2 activity and phosphorylation of the adaptors by the kinase. 30, 31 To determine if the Lnk/JAK2 interaction has a pathophysiological significance in MPNs, we To identify other domains of Lnk involved in its interaction with JAK2, we performed GST pull-down experiments using GST fusion proteins expressing either the Lnk SH2 domain (SH2), the SH2 inactive form (R364M), the PH domain alone (PH) or together with the amino-terminus region (NPH, Figure 5A ) and immunoblotted with anti-phospho-specific JAK2, anti-phosphotyrosine and anti-JAK2 antibodies.
A stronger interaction between Lnk SH2 domain and JAK2-V617F was detected compared to JAK2-WT ( Figure 5C , right panels). However, binding was now observed with the NPH and R364M
proteins. These results indicate that the expression of the V617F mutation modifies the binding affinity between JAK2 and the adaptor, but not its specificity for Lnk N-terminal region, as shown by the lack of association with the PH domain alone ( Figure 5C ).
Lnk SH2 domain is necessary for inhibiting JAK2-V617F-mediated proliferation.
Lnk is a potent inhibitor of cytokine-dependent cell growth in normal hematopoietic cells. Figure 7B ). This result shows that the SH2 domain is important for inhibiting multilineage cell growth. In this context, the adaptor APS could not replace Lnk function at the progenitor level.
Expression of WT Lnk reestablished normal numbers of CFU-GEMM colonies in
In contrast to CFU-GEMM, analysis of CFU-Meg colonies showed that the R364M mutant displayed a similar effect as the W270A form ( Figure 7C ). Together, these results indicate that the individual domains and Y536 of Lnk contribute differently to its inhibitory function during expansion of multilineage and megakaryocytic progenitors.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From DISCUSSION Lnk-deficient mice display a phenotype reminiscent of MPNs that has suggested a role for Lnk in the development of these diseases. Recently, the first Lnk mutations in ET and PMF patients have been identified. 22 We confirm that the prevalence of such mutations is rare (5% or less) in JAK2-WT Recent studies have shown that Lnk mRNA levels were also elevated in myelodysplastic syndromes and acute myeloid leukemia cells. 32 Together with our data on MPNs, these results suggest a relevant role for Lnk in these proliferative hemopathies.
On the other hand, the data on the inhibition of JAK2-V617F-mediated responses suggest that
Lnk is an important inhibitor of mutated JAK2, similarly to the JAK/STAT inhibitor SOCS2. 35 Interestingly, Lnk and SOCS2 can inhibit cytokine signaling through interaction with both the cytokine receptor and JAK2. 11, 18, 34 In contrast, SOCS3, who acts mainly on the kinase, is unable to inhibit JAK2-V617F, but rather enhances its kinase activity. 36 These results suggest that regulation of the mutated JAK2 is complex and that it may require the combination of several inhibitory mechanisms.
Our analysis of JAK2 activation status in MPN platelets has shown a difference between JAK2-WT and JAK2-V617F MPN samples that correlated with the level of Lnk expression in these patients.
This suggests a distinct Lnk-mediated regulatory mechanism for each JAK2 form. We and others have shown that Lnk does not significantly inhibit the initial activation of cytokine-mediated signaling pathways, but it rather diminishes the duration of their activation after cytokine stimulation. 16, 17, 21, 27 Consisting with this, we have observed a prolonged phosphorylation of JAK2 in V617F-expressing MPN cells at longer TPO-stimulation times that suggests Lnk inability to inhibit the kinase activation (data not shown). As for JAK2-WT MPN patients, the regulation of JAK2 activation appears more complex, possibly involving a molecular event, yet to be characterized, that regulates the kinase activity in these patients.
For
showed for the first time that this interaction occurs in platelets derived from RT and MPN (WT and mutated JAK2) patients. Moreover, we found that Lnk binding to activated JAK2 is required for the phosphorylation of the adaptor by the kinase and this function is dependent on the Lnk SH2 domain.
However, the role of Lnk phosphorylation on JAK2 inhibition is still unclear. Interestingly, HEL cells expressing Lnk mutated at Y536 (Y536F) displayed a significant reduction in Lnk phosphorylation and JAK2-V617F down-regulation, suggesting a role for this tyrosine in both JAK2-mediated Lnk phosphorylation and inhibitory function (A.A. and L.V., unpublished data). In addition, our GST pulldown experiments revealed a novel moderate interaction involving the N-terminal region of Lnk that enables it to associate with inactive JAK2. A similar binding site has been reported for SH2-B and APS, the other members of the Lnk family. In these proteins, the second JAK2-binding site includes the PH domain and the PH-SH2 domain linker region and appears to be inhibitory in nature. 30, 31, 37 For the Lnk protein, we showed that this site does not involve the PH domain, contrary to the recent report by Gery et al. 19 This discrepancy might be due to the length of the PH domain fragment used in each study. Furthermore, we observed that in the presence of the V617F mutation, JAK2 binds stronger to this second Lnk site, suggesting that the mutant kinase displays a different affinity for the adaptor than the WT form. It is then conceivable that the change in JAK2 binding affinity for this site may allow a stronger Lnk inhibition of JAK2 at the basal level. However, it will also affect the kinase subsequent interaction with Lnk SH2 domain, resulting in failure to inhibit JAK2-V617F cytokine-mediated activation. Our recent identification of an Lnk mutation in this region further supports this model. The studies presented here on Lnk -/-Lin -progenitors expressing either WT or mutant forms of Lnk have helped to better define its inhibitory role in the expansion of hematopoietic progenitors.
Indeed, we showed that the SH2 domain contributes mainly to inhibition of the proliferation of .05 denoting statistical significance: *P = .0076; ** P < .0001; ***P = .004. All patients were studied in duplicate. RT, reactive thrombocytosis; PV, polycythemia vera; PMF, primary myelofibrosis. For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
